Abstract
Adjuvant aromatase inhibitors (AIs) are now the standard of care for postmenopausal women with hormone-receptor–positive early-stage breast cancer. Which is the optimal AI and how it should be used remain open questions; however, in the large clinical trials in which adjuvant AIs (either in lieu of tamoxifen or sequentially after tamoxifen) have been investigated, researchers have noted improvements in patient outcomes, largely in disease-free survival (DFS). In all the trials that have included AIs, musculoskeletal (MS) and joint complaints were more common in patients who received an AI than in those who received tamoxifen alone. For example, in the ATAC trial (Journal Watch Women’s Health Sep 24 2002), in which 5 years of tamoxifen was compared with 5 years of …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
